News News Select Year All Years 2026 (33) 2025 (34) 2024 (29) 2023 (30) 2022 (33) 2021 (27) 2020 (34) 2019 (32) 2018 (42) 2017 (35) 2016 (43) 2015 (53) 2014 (26) 2013 (21) 2012 (16) 2011 (6) 2010 (4) 2009 (5) 2007 (1) 2006 (1) Search News Found 505 Results Page 48 of 51« First«...102030...4647484950...»Last » January 31, 2013 DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D Activities January 15, 2013 DBV Technologies and INRA receive funding to develop pediatric bronchiolitis (‘RSV’) vaccine: RSV-NanoViaSkin December 18, 2012 DBV Technologies’ 2013 Financial calendar November 14, 2012 DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children October 16, 2012 DBV Technologies and Centre d’Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement October 15, 2012 First nine months topline and clinical and business highlights August 2, 2012 DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults July 26, 2012 Half Year 2012 results and R&D highlights: DBV Technologies on track July 19, 2012 DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor June 18, 2012 DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congress Page 48 of 51« First«...102030...4647484950...»Last »